Brief: Promore Pharma Granted EU Patent Regarding Treatment Of Chronic Wounds

PMD Device Solutions AB

10/08/2022 11:41

Aug 10 (Reuters) - Promore Pharma AB  PROMO.ST :
    * PROMORE PHARMA GRANTED EU PATENT REGARDING TREATMENT OF
CHRONIC
WOUNDS
    * HAS RECEIVED A GRANTED PATENT IN EUROPEAN UNION FOR USE OF
CANDIDATE DRUG ROPOCAMPTIDE (LL-37) FOR TREATMENT OF CHRONIC
WOUNDS
    * PATENT PERIOD EXTENDS UNTIL AT LEAST NOVEMBER 2034, WITH
POSSIBILITIES OF FURTHER PATENT EXTENSION

Source text for Eikon:  ID:nMFNc7dz7N 
Further company coverage:  PROMO.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))